癌症相关肺栓塞的门诊管理:系统综述与荟萃分析
该系统综述与荟萃分析检索了多个数据库至2024年5月30日,纳入19项研究共1675例门诊管理的癌症相关肺栓塞患者。汇总30天全因死亡率为1.74%(95%CI 0.99-3.03%),大出血为2.71%(95%CI 1.51-4.83%),复发性VTE为1.26%(95%CI 0.53-3.00%),提示经选择的患者门诊管理可能安全。
要点
- 经选择的癌症相关肺栓塞患者门诊管理30天全因死亡率仅1.74%。
- 30天大出血和复发性VTE发生率分别为2.71%和1.26%。
- 仍需更大规模前瞻性研究验证并优化风险分层方案。
核心结论
- 经选择的癌症相关肺栓塞患者门诊管理短期死亡率、大出血和复发性VTE发生率低,可能为安全策略。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane Central和Scopus数据库从建库至2024年5月30日。
- 纳入随机对照试验、队列研究和病例对照研究,要求至少10例患者,共纳入19项研究(13篇全文、6篇仅摘要),1675例门诊管理患者。
- 采用随机效应模型进行荟萃分析,用I2统计量评估异质性。
主要发现
- 30天全因死亡汇总率为1.74%(95%CI 0.99-3.03%;I2=0%;691例患者,6篇全文)。
- 30天大出血汇总率为2.71%(95%CI 1.51-4.83%;I2=0%;406例患者,6篇全文)。
- 30天复发性VTE汇总率为1.26%(95%CI 0.53-3.00%;I2=0%;396例患者,5篇全文)。
- 14项研究报告了癌症相关肺栓塞门诊管理标准。
临床怎么用
- 对经选择的癌症相关肺栓塞患者,可考虑门诊管理,但需依据研究报道的标准进行风险筛选。
局限性
- 需更大规模前瞻性研究确认 findings 并完善风险分层方案。
- 纳入研究包含仅摘要发表的研究,可能影响证据质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outpatient management of pulmonary embolism (PE) remains controversial in patients with cancer due to their higher risks of mortality, recurrent venous thromboembolism (VTE) and bleeding complications. This systematic review and meta-analysis aimed to evaluate the safety and feasibility of outpatient management of cancer-associated PE. METHODS: We searched MEDLINE, Embase, Cochrane Central and Scopus databases from inception to 30 May 2024 for studies on outpatient management of cancer-associated PE. Eligible studies included randomised controlled trials, cohort studies and case-control studies with at least 10 patients. The primary outcome was 30-day all-cause mortality; secondary outcomes included VTE-related mortality, major bleeding and recurrent VTE at 30 days. Meta-analysis was performed using random effects models and heterogeneity was assessed with the I2-statistic. RESULTS: 19 studies (13 full articles, six abstracts only) with a total of 1675 patients managed as outpatients were identified. Criteria for outpatient management of cancer-associated PE were reported in 14 studies. The pooled 30-day all-cause mortality rate was 1.74% (95% CI 0.99-3.03%; I2=0%; 691 patients, six full articles). The 30-day major bleeding pooled rate was 2.71% (95% CI 1.51-4.83%; I2=0%; 406 patients, six full articles) and the 30-day recurrent VTE pooled rate was 1.26% (95% CI 0.53-3.00%; I2=0%; 396 patients, five full articles). CONCLUSIONS: Selected patients with cancer-associated PE managed as outpatients appear to have low short-term rates of mortality, major bleeding and recurrent VTE, suggesting this may be a safe strategy. Further research with larger, prospective studies is needed to confirm these findings and refine risk stratification protocols.
引用
- Delluc, Pradier, Siegal, et al. Outpatient management of cancer-associated pulmonary embolism: a systematic review and meta-analysis. Eur Respir J. 2025. PMID: 39603673. doi:10.1183/13993003.01596-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。